Dopamine Modulation by Antipsychotic in Schizophrenia

Abstract

Schizophrenia is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms. The dopamine hypothesis of schizophrenia posits that hyperactivity of dopamine pathways, particularly in the mesolimbic pathway, contributes to the positive symptoms of the illness. Antipsychotic medications, the primary pharmacological treatment for schizophrenia, exert their therapeutic effects largely through modulation of dopamine neurotransmission. This document explores the mechanisms by which antipsychotic drugs affect dopamine pathways. Both first-generation antipsychotics (FGAs) and second-generation antipsychotics (SGAs) primarily act as dopamine receptor antagonists, blocking dopamine receptors, particularly the D2 receptor subtype. However, SGAs exhibit a more complex pharmacological profile, often including serotonin receptor antagonism (e.g., 5-HT2A) in addition to dopamine receptor blockade. This serotonin antagonism is thought to contribute to the improved side effect profile and efficacy against negative symptoms observed with some SGAs. The document further examines the regional specificity of antipsychotic effects on dopamine release and metabolism, considering the mesolimbic, mesocortical, nigrostriatal, and tuberoinfundibular pathways. Understanding these mechanisms is crucial for optimizing antipsychotic treatment strategies, minimizing adverse effects such as extrapyramidal symptoms (EPS) and hyperprolactinemia, and developing novel therapeutic interventions targeting dopamine and other neurotransmitter systems in schizophrenia.